A Study of the Effectiveness and Safety of SP2086 to Treat Type 2 Diabetes

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2011
SP2086 is a new dipeptidy1 peptidase(DPP)-4 inhibitors. This study aims to explore the effective dose range of SP2086 in Patients with type 2 diabetes.
Epistemonikos ID: 05843b683aed81cfd70f87d856e5a06a635dc6dc
First added on: May 11, 2024